27 thoughts on “🏴‍☠️ VERTEX PHARMACEUTICALS USD (VRTX-USD)”

  1. #VRTX is “In Play”

    Vertex Pharma to Acquire Semma Therapeutics for $950 mln in cash, with a goal of developing curative cell-based treatments for Type 1 Diabetes:

    Vertex will acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash.

    Semma has demonstrated a differentiated approach to treat type 1 diabetes, a serious disease affecting over one million people in the United States alone.

    Semma has made two major scientific advances: the ability to produce large quantities of functional human pancreatic beta cells that restore insulin secretion and ameliorate hypoglycemia in animal models and a novel device that encapsulates and protects these cells from the immune system, enabling durable implantation without the need for ongoing immunosuppressive therapy.

  2. #VRTX is “In Play”

    Vertex Pharma and Ribometrix, Inc. enter into strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases:

    • The collaboration will combine Ribometrix”s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA structures with Vertex”s scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix.

    • Under the terms of the agreement, Vertex will pay Ribometrix approximately $20 million upfront, which includes an equity investment in the company. Initially, Ribometrix will undertake two discovery programs with Vertex, and Vertex has an option to add a third program. Following discovery and optimization of novel therapeutic molecules, Vertex has the option to take an exclusive global license for the development and commercialization of molecules for that program. Ribometrix is eligible to receive more than $700 million in total potential payments based upon the successful achievement of specified research, development, regulatory and commercial milestones as part of the collaboration. In addition, Vertex will pay tiered royalties on future net global sales on any products that result from the collaboration.

  3. VRTX is “In Play”

    Vertex Pharma: Spanish Government has approved terms for the national reimbursement of ORKAMBI and SYMKEVI in combination with KALYDECO for eligible patients in Spain living with cystic fibrosis

    Vertex Pharma receives FDA approval for Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation:

    Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population.

    Vertex Pharma: FDA has approved TRIKAFTA in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene –halted– ….

    https://www.facebook.com/groups/493863300973045/permalink/877725049253533/

  4. VRTX is “In Play”

    Vertex Pharma beats by $0.10, reports revs in-line; affirms recently updated revenue outlook:

    Reports Q3 (Sep) earnings of $1.23 per share, excluding non-recurring items, $0.10 better than the S&P Capital IQ Consensus of $1.13; revenues rose 21.1% year/year to $949.83 mln vs the $942.9 mln S&P Capital IQ Consensus.

    Vertex today reiterated its 2019 revenue guidance that was updated on October 21, 2019.

    TOTAL product revenues of $ 3.70 to 3.75 billion

    VRTX, (Trade) has reported earnings of 1.23 per share versus last year’s earnings of 1.09 per share.

    Vertex Pharma receives MAA for VX-445, tezacaftor, and ivacaftor triple combination treatment in cystic fibrosis:

    The European Medicines Agency has validated the Marketing Authorization Application (MAA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen. The submission was supported by previously disclosed positive results of two global Phase 3 studies in people with cystic fibrosis: a 24-week study in people with one F508del mutation and one minimal function mutation and a 4-week study in people with two F508del mutations. Both Phase 3 studies showed statistically significant improvements in lung function, which was the primary endpoint, and in all key secondary endpoints. In these studies, the triple combination regimen was generally well tolerated.

    Vertex Pharma announces concurrent publication in The New England Journal of Medicine and The Lancet of results from two Phase 3 studies of TRIKAFTA:

    The co announced the concurrent publication in The New England Journal of Medicine (NEJM) and The Lancet of results from two Phase 3 studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation. Data highlighting primary and secondary endpoints from a 24-week Phase 3 study in 403 people with one F508del mutation and one minimal function mutation (F/MF) in the CFTR gene were published in NEJM. In addition, The Lancet published data highlighting primary and secondary endpoints from a 4-week Phase 3 study in 107 people with two F508del mutations (F/F). Both studies met primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful improvements in lung function and other measures of disease. In these studies, TRIKAFTA was generally well tolerated.

    Acquired VERTEX PHARMACEUTICALS USD (VRTX-USD). via ROBINHOOD at approximately 194.79. (Shares: 1) bringing the Average Price Paid (APP) to about 194.605.

    Adjusted Sell Stop to 194.85. from 192.3.

    https://www.facebook.com/groups/493863300973045/permalink/877725049253533/

  5. #VRTX IS IN PLAY

    Adjusted Multiplier to 2. from 4.

    Adjusted Buy Stop to 219.41. from 223.87.

    Adjusted Sell Stop to ASSESSING. from 219.53.

    Transferred 100% of Trade Money to Investment Money (Shares: 3) bringing the Average Price Paid (APP) to about 199.8801.

    Converted 100% of Investment/Trade Money at approximately 219.53. (Shares: 12) generating about +‭9.8309% of NEW Commission FREE Cash Reserve.

    https://www.facebook.com/groups/493863300973045/permalink/877725049253533/

  6. #VRTX IS IN PLAY

    Adjusted Multiplier to 3. from 2.

    Adjusted Buy Stop to 244.98. from 234.60.

    Adjusted Sell Stop to 240.51. from 228.31.

    Acquired at approximately 234.60. (Shares: 2) bringing the Average Price Paid (APP) to about 234.60.

    Converted 100% of Investment/Trade Money at approximately 228.31. (Shares: 4) generating about +4.0232% of NEW Commission FREE Cash Reserve.

    https://www.facebook.com/groups/493863300973045/permalink/877725049253533/

  7. #VRTX IS IN PLAY

    Adjusted Multiplier to 4. from 3.

    Adjusted Buy Stop to 230.42. from 244.98.

    Adjusted Sell Stop to ASSESSING. from 240.51.

    Acquired at approximately 244.98. (Shares: 3) bringing the Average Price Paid (APP) to about 244.98.

    Converted 100% of Investment/Trade Money at approximately 240.51. (Shares: 2) generating about +2.5192% of NEW Commission FREE Cash Reserve.

    https://www.facebook.com/groups/493863300973045/permalink/877725049253533/

  8. #VRTX IS IN PLAY

    Multiplier (X) to 0.970424. from 4.000000.

    Buy Stop Limit (BSL) to 291.56. from 230.42.

    Sell Stop Limit (SSL) to 282.84. from ASSESSING.

    Converted Cash Reserve (CR) to Trade (T) at approximately 230.42. (Share: 4) bringing the Average Price Paid (APP) to about 236.66.

    Converted Trade (T) to Investment (I) (Share: 7) bringing the Average Price Paid (APP) to about 236.66.

    Just to reiterate, I placed the following order(s):
    + Buy 1. Shares @ 291.56; Limit: 291.56. & Stop: 291.55.
    – Sell 7. Shares @ 282.84; Limit 282.84. & Stop: 282.85.

    https://www.facebook.com/groups/493863300973045/?post_id=877725049253533

  9. #VRTX IS IN PLAY

    Multiplier (X) to 0.964362. from 0.970424.

    Buy Stop Limit (BSL) to 293.40. from 291.56.

    Sell Stop Limit (SSL) to 287.37. from 282.84.

    Converted Cash Reserve (CR) to Trade (T) at approximately 291.56. (Share: 1) bringing the Average Price Paid (APP) to about 291.56.

    Converted Trade (T) to Investment (I) (Share: 1) bringing the Average Price Paid (APP) to about 243.52.

    Just to reiterate, I placed the following order(s):
    + Buy 1. Shares @ 293.40; Limit: 293.40. & Stop: 293.39.
    – Sell 8. Shares @ 287.37; Limit 287.37. & Stop: 287.38.

    https://www.facebook.com/groups/493863300973045/?post_id=877725049253533

  10. #VRTX IS IN PLAY

    Multiplier (X) to 2.165911. from 0.964362.

    Buy Stop Limit (BSL) to 292.59. from 293.40.

    Sell Stop Limit (SSL) to ASSESSING. from 287.37.

    Converted Cash Reserve (CR) to Trade (T) at approximately 293.40. (Share: 1) bringing the Average Price Paid (APP) to about 293.40.

    Converted Investment (I) to Cash Reserve (CR) at approximately 287.37. (Share: 8) generating about +18.00% ROI (Return on Investment).

    Just to reiterate, I placed the following order(s):
    + Buy 2. Shares @ Limit Price: 292.59.

    https://www.facebook.com/groups/493863300973045/?post_id=877725049253533

  11. #VRTX IS IN PLAY

    Multiplier (X) to 2.683926. from 2.907807.

    Buy Stop Limit (BSL) to 232.51. from 217.94.

    Sell Stop Limit (SSL) to 232.16. from XIIMM.

    Converted Cash Reserve (CR) to Trade (T) at approximately 217.94. (Share: 2) bringing the Average Price Paid (APP) to about 262.892.

    Converted Trade (T) to Investment (I) (Share: 2) bringing the Average Price Paid (APP) to about 217.94.

    Just to reiterate, I placed the following order(s):
    + Buy 2. Shares @ Limit Price: 232.51.
    + Sell 2. Shares @ Limit Price: 232.16.

    Data:
    http://xiimm.net/collective/2020/12/28/vertex-pharmaceuticals-usd-vrtx-usd/

    Graphics:
    http://xiimm.net/collective/vrtx/

Leave a Reply